These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 7585593

  • 21. Structure-activity relationship of 3-substituted N-(pyridinylacetyl)-4- (8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene )- piperidine inhibitors of farnesyl-protein transferase: design and synthesis of in vivo active antitumor compounds.
    Njoroge FG, Vibulbhan B, Rane DF, Bishop WR, Petrin J, Patton R, Bryant MS, Chen KJ, Nomeir AA, Lin CC, Liu M, King I, Chen J, Lee S, Yaremko B, Dell J, Lipari P, Malkowski M, Li Z, Catino J, Doll RJ, Girijavallabhan V, Ganguly AK.
    J Med Chem; 1997 Dec 19; 40(26):4290-301. PubMed ID: 9435898
    [Abstract] [Full Text] [Related]

  • 22. Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice.
    Zhang YA, Nemunaitis J, Scanlon KJ, Tong AW.
    Gene Ther; 2000 Dec 19; 7(23):2041-50. PubMed ID: 11175317
    [Abstract] [Full Text] [Related]

  • 23. Antitumor activity of orally bioavailable farnesyltransferase inhibitor, ABT-100, is mediated by antiproliferative, proapoptotic, and antiangiogenic effects in xenograft models.
    Ferguson D, Rodriguez LE, Palma JP, Refici M, Jarvis K, O'Connor J, Sullivan GM, Frost D, Marsh K, Bauch J, Zhang H, Lin NH, Rosenberg S, Sham HL, Joseph IB.
    Clin Cancer Res; 2005 Apr 15; 11(8):3045-54. PubMed ID: 15837760
    [Abstract] [Full Text] [Related]

  • 24. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro.
    End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, Venet M, Sanz G, Poignet H, Skrzat S, Devine A, Wouters W, Bowden C.
    Cancer Res; 2001 Jan 01; 61(1):131-7. PubMed ID: 11196150
    [Abstract] [Full Text] [Related]

  • 25. [Inhibitors of farnesyl transferase in oncology: from basic research to pharmaceutical research].
    Lavelle F.
    C R Seances Soc Biol Fil; 1997 Jan 01; 191(2):211-9. PubMed ID: 9255348
    [Abstract] [Full Text] [Related]

  • 26. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.
    Liu M, Bryant MS, Chen J, Lee S, Yaremko B, Lipari P, Malkowski M, Ferrari E, Nielsen L, Prioli N, Dell J, Sinha D, Syed J, Korfmacher WA, Nomeir AA, Lin CC, Wang L, Taveras AG, Doll RJ, Njoroge FG, Mallams AK, Remiszewski S, Catino JJ, Girijavallabhan VM, Bishop WR.
    Cancer Res; 1998 Nov 01; 58(21):4947-56. PubMed ID: 9810004
    [Abstract] [Full Text] [Related]

  • 27. Inhibition of farnesyl protein transferase by monoterpene, curcumin derivatives and gallotannin.
    Chen X, Hasuma T, Yano Y, Yoshimata T, Morishima Y, Wang Y, Otani S.
    Anticancer Res; 1997 Nov 01; 17(4A):2555-64. PubMed ID: 9252680
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Suppression of human pancreatic cancer growth in BALB/c nude mice by manumycin, a farnesyl:protein transferase inhibitor.
    Ito T, Kawata S, Tamura S, Igura T, Nagase T, Miyagawa JI, Yamazaki E, Ishiguro H, Matasuzawa Y.
    Jpn J Cancer Res; 1996 Feb 01; 87(2):113-6. PubMed ID: 8609057
    [Abstract] [Full Text] [Related]

  • 30. The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras.
    Cohen-Jonathan E, Evans SM, Koch CJ, Muschel RJ, McKenna WG, Wu J, Bernhard EJ.
    Cancer Res; 2001 Mar 01; 61(5):2289-93. PubMed ID: 11280800
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
    Gourdeau H, Genne P, Kadhim S, Bibeau L, Duchamp O, Ouellet F, deMuys JM, Bouffard DY, Attardo G.
    Cancer Chemother Pharmacol; 2002 Dec 01; 50(6):490-6. PubMed ID: 12451476
    [Abstract] [Full Text] [Related]

  • 33. Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis.
    Nørgaard P, Law B, Joseph H, Page DL, Shyr Y, Mays D, Pietenpol JA, Kohl NE, Oliff A, Coffey RJ, Poulsen HS, Moses HL.
    Clin Cancer Res; 1999 Jan 01; 5(1):35-42. PubMed ID: 9918200
    [Abstract] [Full Text] [Related]

  • 34. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors.
    Koyanagi N, Nagasu T, Fujita F, Watanabe T, Tsukahara K, Funahashi Y, Fujita M, Taguchi T, Yoshino H, Kitoh K.
    Cancer Res; 1994 Apr 01; 54(7):1702-6. PubMed ID: 8137285
    [Abstract] [Full Text] [Related]

  • 35. A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines.
    Sepp-Lorenzino L, Ma Z, Rands E, Kohl NE, Gibbs JB, Oliff A, Rosen N.
    Cancer Res; 1995 Nov 15; 55(22):5302-9. PubMed ID: 7585592
    [Abstract] [Full Text] [Related]

  • 36. In vitro growth and drug sensitivity of tumor colony-forming units from human tumor xenografts.
    Taetle R, Koessler AK, Howel SB.
    Cancer Res; 1981 May 15; 41(5):1856-60. PubMed ID: 7214353
    [Abstract] [Full Text] [Related]

  • 37. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice.
    Kohl NE, Omer CA, Conner MW, Anthony NJ, Davide JP, deSolms SJ, Giuliani EA, Gomez RP, Graham SL, Hamilton K.
    Nat Med; 1995 Aug 15; 1(8):792-7. PubMed ID: 7585182
    [Abstract] [Full Text] [Related]

  • 38. Natural inhibitors for protein prenyltransferase.
    Lee S, Park S, Oh JW, Yang C.
    Planta Med; 1998 May 15; 64(4):303-8. PubMed ID: 9619109
    [Abstract] [Full Text] [Related]

  • 39. Farnesyl: proteintransferase inhibitors as agents to inhibit tumor growth.
    Omer CA, Anthony NJ, Buser-Doepner CA, Burkhardt AL, deSolms SJ, Dinsmore CJ, Gibbs JB, Hartman GD, Koblan KS, Lobell RB, Oliff A, Williams TM, Kohl NE.
    Biofactors; 1997 May 15; 6(3):359-66. PubMed ID: 9288406
    [Abstract] [Full Text] [Related]

  • 40. A peptidomimetic inhibitor of ras functionality markedly suppresses growth of human prostate tumor xenografts in mice. Prospects for long-term clinical utility.
    Sirotnak FM, Sepp-Lorenzino L, Kohl NE, Rosen N, Scher HI.
    Cancer Chemother Pharmacol; 2000 May 15; 46(1):79-83. PubMed ID: 10912583
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.